Bladder Cancer | Niche and Rare Pharmacor | G7 | 2015

Bladder cancer is one of the ten most common cancers worldwide that can afflict both genders and is the 13th most common cause of death associated with cancer. A mixture of immunotherapy (BCG vaccine), chemotherapies, and surgery are currently used to treat bladder cancer. The management of early-stage bladder cancer contributes to a significant healthcare burden due to the high risk of recurrence, frequent monitoring of the disease, and high treatment costs.

Using primary research conducted with U.S. and European bladder cancer medical oncologists who have expertise treating bladder cancer, this report provides a comprehensive analysis of the competitive landscape and market opportunities for bladder cancer. This report includes an analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies. Of currently approved therapies for treating bladder cancer, only valrubicin (Endo’s Valstar) and vinflunine (Pierre Fabre’s Javlor) do not yet face generic competition, even though valrubicin is no longer patent protected.

launch Related Market Assessment Reports